Explain this page
Arphra AIPlain-English read on Scienture Holdings, Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
No peer list available for SCNX.
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.71% | +2.74% | -1.92% | -6.00% | -28.87% | -22.84% | -55.28% | -94.75% | -94.75% | -94.75% | -94.75% |
Aftermarket
LiveLast trade
$0.39
23 sh
Bid
$0.39
1 sh
Ask
$0.41
1 sh
Spread
$0.027
Sector & industry today
LiveSectors
- Energy+0.98%
- Technology+0.68%
- Basic Materials+0.55%
- Industrials+0.42%
- Consumer Defensive+0.13%
- Healthcare-0.48%
- Real Estate-0.54%
- Consumer Cyclical-0.63%
- Financial Services-0.66%
- Communication Services-0.94%
- Utilities-1.14%
Top industries (issuer's industry highlighted)
- Medical - Healthcare Information Services-1.31%
- Engineering & Construction+2.96%
- Hardware, Equipment & Parts+2.52%
- Financial - Data & Stock Exchanges-2.40%
- Industrial Materials+2.32%
- Consulting Services+2.30%
- Electrical Equipment & Parts+2.29%
- Coal+2.28%
- Advertising Agencies-2.19%
- Drug Manufacturers - Specialty & Generic-1.99%
- Copper+1.85%
- Industrial - Machinery+1.80%
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipelineglobenewswire.com·May 07, 2026
- SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041globenewswire.com·May 06, 2026
- SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041globenewswire.com·May 06, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|